Pharmicell Co., Ltd

As of June 30, 2026, Pharmicell Co., Ltd carries a market capitalization of 777.65B, placing it among publicly traded companies globally. Its enterprise value stands at 737.51B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pharmicell Co., Ltd's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Pharmicell Co., Ltd has 60.00M shares outstanding.

As of June 30, 2026, Pharmicell Co., Ltd trades at a trailing price-to-earnings ratio of 16.71. The price-to-sales ratio is 5.72, and the price-to-book ratio stands at 5.42.

As of June 30, 2026, Pharmicell Co., Ltd trades at an EV/EBITDA multiple of 15.66 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.43 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.74 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Pharmicell Co., Ltd trades at an EV/FCF ratio of 28.24, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 737.51B versus a market cap of 777.65B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pharmicell Co., Ltd maintains a current ratio of 7.15, meaning it holds 7.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Pharmicell Co., Ltd posted a return on equity (ROE) of 38.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 27.99 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 30.50, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 33.39, useful for judging operating efficiency across full business cycles. The company generates approximately 772.39M in revenue per employee across its workforce of 176.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.95 indicates how many times Pharmicell Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Pharmicell Co., Ltd recorded 5.90B in income tax expense. That works out to an effective tax rate of 12.58, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 46.91B, leaving 46.53B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Pharmicell Co., Ltd's stock has declined approximately 24.03% over the past 52 weeks. The 50-day moving average sits at 11,447.40, while the 200-day moving average is 13,914.25.

Over the twelve months ended June 30, 2026, Pharmicell Co., Ltd generated 135.94B in revenue and converted that into 46.53B in net income, yielding earnings per share of 775.55. EBITDA reached 47.08B, while operating income came in at 44.07B.

As of June 30, 2026, Pharmicell Co., Ltd holds 65.67B in cash and equivalents against 25.53B in total debt, resulting in a net debt position of 9.97B. Total book value stands at 143.37B, with working capital of 98.73B providing operational flexibility.

Pharmicell Co., Ltd produced 41.02B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.90B in capital expenditures, free cash flow totaled 26.12B - equivalent to 435.25 per share.

Over the twelve months ended June 30, 2026, Pharmicell Co., Ltd posted a gross margin of 44.44, reflecting its pricing power and cost economics. The operating margin of 32.42 and net profit margin of 34.23 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pharmicell Co., Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.36, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -1.76, meaning Pharmicell Co., Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Pharmicell Co., Ltd's most recent stock split took place on May 2, 2012 with a 161:171 split ratio.

As of June 30, 2026, Pharmicell Co., Ltd has an Altman Z-Score of 14.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.